First-in-human phase I study of a ROR1-targeting bispecific T-cell engager (NVG-111) shows evidence of efficacy in patients with relapsed/refractory CLL and MCL. Parag Jasani,William Townsend, Samir Asher, Sarrah Tayabali,David Tucker,Sarah Cook, Toby Batten, David Granger,Mittal Shah, Kieran O'Donovan,Amit C. NathwaniJOURNAL OF CLINICAL ONCOLOGY（2022）引用 1|浏览9暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
